Lexeo Therapeutics, Inc. Common StockLXEONASDAQ
Loading
R&D Expenses Over TimeContracting
Percentile Rank80
3Y CAGR+10.3%
5Y CAGR+72.5%
Year-over-Year Change
Research and development spending
3Y CAGR
+10.3%/yr
Annual compound
5Y CAGR
+72.5%/yr
Recent deceleration
Percentile
P80
Within normal range
vs 5Y Ago
15.3x
Strong expansion
Streak
1 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| TTM | $65.95M | -11.0% |
| 2024 | $74.09M | +39.5% |
| 2023 | $53.13M | +8.1% |
| 2022 | $49.16M | +9.0% |
| 2021 | $45.12M | +944.8% |
| 2020 | $4.32M | - |